A Phase III, Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Node-Positive Breast Cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide Followed by DD Paclitaxel (DD-P); DD AC Followed by DD Paclitaxel Plus Gemcitabine (DD AC-PG).

Trial Profile

A Phase III, Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Node-Positive Breast Cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide Followed by DD Paclitaxel (DD-P); DD AC Followed by DD Paclitaxel Plus Gemcitabine (DD AC-PG).

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Dec 2016

At a glance

  • Drugs Gemcitabine (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin; Paclitaxel
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 28 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 08 Jun 2016 Planned End Date changed from 1 Mar 2016 to 1 Jun 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top